ORTEXORTEX News
Tracking CAVA? Get live short interest, options flow, and signals on ORTEX.Sign up free →
CA
Trader NoteCAVA

Morgan Stanley Upgrade Meets a Stock Down 23% in a Month

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 15 Jul 2026, 20:20

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

CAVA heads into mid-July with a sharp divide between what Wall Street is saying today and what the chart has been doing all month.

The most striking development this week is a Morgan Stanley upgrade. Analyst Brian Harbour moved CAVA to Overweight from Equal-Weight on July 15, lifting his target to $90. That's a meaningful shift from a bellwether firm — and it lands against a backdrop where the stock closed at $69.97, down 3.5% on Tuesday and off 23% over the past month. The upgrade implies roughly 29% upside from current levels. It follows UBS lifting CAVA to Buy in early June with a $90 target. The Street's consensus is still a hold, with eight hold ratings against four outperforms, and the mean price target of $93 sits well above where the stock is trading. The direction of recent analyst moves is constructive: multiple firms have raised targets post-Q1 results, and the bull case centres on CAVA's unit expansion roadmap to 1,000+ locations by 2032, digital ordering advantages, and above-average same-store sales growth. The bear case is simpler — management flagged a potential same-store sales slowdown for the rest of the year, and at roughly 138x trailing earnings and an EV/EBITDA near 49x, the valuation leaves little room for execution misses.

Short positioning tells an interesting secondary story. At 11% of free float, CAVA carries a genuinely elevated short position — but it has been easing, not building. Short interest has fallen roughly 7% over the past month, pulling back from above 14 million shares in early June to 12.76 million now. The borrow market is extremely relaxed: availability is around 488%, meaning there are nearly five shares available to lend for every share already borrowed, close to the loosest the pool has been over the past 52 weeks. Cost to borrow is negligible at 0.46%, down 19% on the week. Nothing in the lending data suggests squeeze pressure or aggressive new short positioning — the shorts appear to be gradually reducing, not adding. Options positioning reinforces the low-pressure read: the put/call ratio of 0.76 is running slightly below its 20-day average of 0.77, with a z-score near zero. There is no elevated demand for downside protection, despite the month's sell-off.

The institutional ownership table adds a layer of context worth noting. Artal Group — a 10% board-represented owner — cut its stake by 3 million shares in mid-June, a $270 million block sale. CEO Brett Schulman sold 33,174 shares on June 15 at $89.43, and the CFO, HR Director, and Chief Accounting Officer all had sales recorded the same day. Net insider activity over the past 90 days shows roughly 3.1 million shares sold for approximately $280 million in proceeds. The sales occurred at prices near $90 — well above where the stock trades today — and the timing, right before a 23% decline, is notable. These were likely pre-planned 10b5-1 disposals, but the scale of the Artal exit in particular is the kind of supply event that can weigh on sentiment.

Fast-casual peers have also had a rough few days. SG — Sweetgreen — was the standout laggard, falling over 14% on Tuesday alone and down 8.4% on the week, amplifying the sector's negative tone. BROS dropped 3.6% on the day. SHAK and CMG held up better over the week, with Shake Shack gaining 9.4% and Chipotle rising 6%. CAVA's roughly flat week — up 0.3% — puts it somewhere in the middle of a diverging peer group.

Earnings history adds one more data point to frame the risk. The Q1 2026 report in late June triggered a 13% one-day decline and a further 8% over the following five days — the stock's sharpest post-earnings reaction in recent memory. The next print is due September 1. With the stock having already retraced sharply from the post-Q1 highs, and the Morgan Stanley upgrade providing a fresh near-term catalyst, the question heading into September is less about valuation and more about whether the same-store sales trajectory can reassure a Street that turned cautious after management's guidance language last quarter.

Stocks in this article

See the live data behind this article on ORTEX.

Open CAVA on ORTEX →

How this article was generated

Generated
15 Jul 2026, 20:24
Data as of
15 Jul 2026, 20:20
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.